Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients

Malignant gastrointestinal stromal tumours (GIST) have a poor prognosis. Since these tumours are resistant to conventional radiation and chemotherapy, surgery has been the mainstay of treatment. However, surgery is usually inadequate for the treatment of malignant GIST. Imatinib, a KIT tyrosine kina...

Descripción completa

Detalles Bibliográficos
Autores principales: Bümming, P, Andersson, J, Meis-Kindblom, J M, Klingenstierna, H, Engström, K, Stierner, U, Wängberg, B, Jansson, S, Ahlman, H, Kindblom, L-G, Nilsson, B
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394385/
https://www.ncbi.nlm.nih.gov/pubmed/12888812
http://dx.doi.org/10.1038/sj.bjc.6600965

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394385/
https://www.ncbi.nlm.nih.gov/pubmed/12888812
http://dx.doi.org/10.1038/sj.bjc.6600965

Ejemplares similares